RE:RE:RE:Neuro is back…I totally agree and they should act by this fall, otherwise the price will go up dramatically as we get additional science releases.
Zero chance that will happen because there is zero clinical data. Pharmas are risk averse. It will take a clinical trial showing efficacy and safety -- and probably more than one -- before any pharma would even consider a buyout.